Business Wire

Sage-ONF Launches Innovative Silicone Synthetic Leather for Future Mobility Interiors

Share

Sage-ONF, a synthetic leather supplier boasting 29 years of experience in design, development, manufacturing and sales, launches serial production of Silicone Synthetic leather. The Sage-ONF plant has begun manufacturing the Silicone Synthetic leather in Shanghai, China.

As consumers continue to demand greater sustainability commitments, this new venture extends Sage-ONF’s heritage of sustainability by delivering Silicone Synthetic leather as an innovative petroleum-free, non-carbon-based product solution for today’s mobility interiors. With a steadfast conviction to continuous innovation and earth-friendly business practices, this new material avoids DMF and plasticizer usage.

“Bringing together our core competencies as Sage-ONF, we bridge the gap between consumer expectations and industry capabilities to provide alternatives that are both environmentally friendly and bolster animal welfare around the globe,” said Robbie Lv, General Manager of Sage-ONF.

Sage and ONF bring 74 years in the automotive interiors business and a deep understanding of cultural trends and design preferences to deliver unparalleled luxury and a soft hand feel that consumers demand for interior mobility needs. Beyond the touch, consumers can have confidence in their interior’s longevity and cleanability—simply wipe stains with a damp cloth to remove them.

However, experience proves that interiors must be tough enough to tackle mile after mile with a super resilient resistance to extreme temperatures. Using UV, hydrolysis, cold crack and flame tests, Sage-ONF ensures long-lasting interiors that enhance the consumer mobility experience. While many claim superiorities in luxury or in sustainability, Sage-ONF exceeds expectations in both realms by using non-solvent and plasticizer-free techniques to create an opulent silicone with ultra-low VOCs.

“By keeping our product, process and mission as our guide, we are pleased to create a silicone synthetic leather that meets the demanding needs of the mobility interior without leather’s known fragility, extra weight, environmental impact and short lifespan,” said Mark Brezenski, Vice President – Asia at Sage, an Asahi Kasei company. “Sage-ONF is proud to deliver interior materials and solutions of tomorrow to OEMs and consumers, today.”

About Sage Automotive Interiors

Sage Automotive Interiors (www.sageautomotiveinteriors.com) is one of the world’s leading providers of automotive interior materials—seating, door panel surfaces and headliners—to automotive Original Equipment Manufacturers (OEMs). Global offices and manufacturing locations include the U.S., South America, EMEA and Asia. Sage’s core strengths are consumer research, sustainability and innovative problem solving for the OEM. Sage’s vision is to continually lead the market in design, engineering and technical capability, supported by world-class manufacturing. Sage Automotive Interiors is an Asahi Kasei company.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Reader Inquiries & Editorial Contacts:
Michele Wascavage, Sage Automotive Interiors
Global Marketing Director
Michele.wascavage@sageai.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye